Cargando…

Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study

BACKGROUND: Chemotherapy and major pelvic surgery are established risk factors for venous thromboembolism (VTE). We evaluate the incidence rate, timing, and factors associated with VTE in patients with bladder cancer who underwent radical cystectomy and peri-operative chemotherapy in routine clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Kelly, Karim, Safiya, Doiron, R. Christopher, Siemens, D. Robert, Booth, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218104/
https://www.ncbi.nlm.nih.gov/pubmed/30417053
http://dx.doi.org/10.3233/BLC-180184
_version_ 1783368402704793600
author Brennan, Kelly
Karim, Safiya
Doiron, R. Christopher
Siemens, D. Robert
Booth, Christopher M.
author_facet Brennan, Kelly
Karim, Safiya
Doiron, R. Christopher
Siemens, D. Robert
Booth, Christopher M.
author_sort Brennan, Kelly
collection PubMed
description BACKGROUND: Chemotherapy and major pelvic surgery are established risk factors for venous thromboembolism (VTE). We evaluate the incidence rate, timing, and factors associated with VTE in patients with bladder cancer who underwent radical cystectomy and peri-operative chemotherapy in routine clinical practice. METHODS: Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients who underwent cystectomy for bladder cancer in Ontario 1994–2013. VTE events within 6 months of before or after cystectomy were identified using diagnostic codes recorded on hospital admissions and emergency department visits. Multivariable logistic regression was used to analyze factors associated with VTE prior to surgery, within 90-days of cystectomy, and 120-days after the start of adjuvant chemotherapy. RESULTS: 4205 patients had cystectomy and 26% (1084/4205) received peri-operative chemotherapy. The overall incidence rate of VTE within 6 months of cystectomy was 9% (363/4205). VTE rate was highest among those patients treated with neoadjuvant chemotherapy (NACT) compared to patients treated with no chemotherapy or only adjuvant chemotherapy (ACT) (12% vs 8% vs 9%, p = 0.002). Among all VTE events, 10%, 28%, and 61% occurred before, during, and after hospitalization for cystectomy. Pre-operative VTE rate was highest among cases treated with NACT (4%) compared to patients with no chemotherapy (<1%) or ACT (<1%) (p < 0.001). VTE within 90 days of surgery was associated with greater length of hospital admission (p < 0.001) across all treatment groups. CONCLUSIONS: A substantial proportion of patients treated with peri-operative chemotherapy will develop VTE. The majority of these occur after discharge from hospital following cystectomy. Extended thromboprophylaxis treatment in high-risk patients including those who receive peri-operative chemotherapy should be considered.
format Online
Article
Text
id pubmed-6218104
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-62181042018-11-07 Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study Brennan, Kelly Karim, Safiya Doiron, R. Christopher Siemens, D. Robert Booth, Christopher M. Bladder Cancer Research Report BACKGROUND: Chemotherapy and major pelvic surgery are established risk factors for venous thromboembolism (VTE). We evaluate the incidence rate, timing, and factors associated with VTE in patients with bladder cancer who underwent radical cystectomy and peri-operative chemotherapy in routine clinical practice. METHODS: Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients who underwent cystectomy for bladder cancer in Ontario 1994–2013. VTE events within 6 months of before or after cystectomy were identified using diagnostic codes recorded on hospital admissions and emergency department visits. Multivariable logistic regression was used to analyze factors associated with VTE prior to surgery, within 90-days of cystectomy, and 120-days after the start of adjuvant chemotherapy. RESULTS: 4205 patients had cystectomy and 26% (1084/4205) received peri-operative chemotherapy. The overall incidence rate of VTE within 6 months of cystectomy was 9% (363/4205). VTE rate was highest among those patients treated with neoadjuvant chemotherapy (NACT) compared to patients treated with no chemotherapy or only adjuvant chemotherapy (ACT) (12% vs 8% vs 9%, p = 0.002). Among all VTE events, 10%, 28%, and 61% occurred before, during, and after hospitalization for cystectomy. Pre-operative VTE rate was highest among cases treated with NACT (4%) compared to patients with no chemotherapy (<1%) or ACT (<1%) (p < 0.001). VTE within 90 days of surgery was associated with greater length of hospital admission (p < 0.001) across all treatment groups. CONCLUSIONS: A substantial proportion of patients treated with peri-operative chemotherapy will develop VTE. The majority of these occur after discharge from hospital following cystectomy. Extended thromboprophylaxis treatment in high-risk patients including those who receive peri-operative chemotherapy should be considered. IOS Press 2018-10-29 /pmc/articles/PMC6218104/ /pubmed/30417053 http://dx.doi.org/10.3233/BLC-180184 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Brennan, Kelly
Karim, Safiya
Doiron, R. Christopher
Siemens, D. Robert
Booth, Christopher M.
Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title_full Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title_fullStr Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title_full_unstemmed Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title_short Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
title_sort venous thromboembolism and peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based study
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218104/
https://www.ncbi.nlm.nih.gov/pubmed/30417053
http://dx.doi.org/10.3233/BLC-180184
work_keys_str_mv AT brennankelly venousthromboembolismandperioperativechemotherapyformuscleinvasivebladdercancerapopulationbasedstudy
AT karimsafiya venousthromboembolismandperioperativechemotherapyformuscleinvasivebladdercancerapopulationbasedstudy
AT doironrchristopher venousthromboembolismandperioperativechemotherapyformuscleinvasivebladdercancerapopulationbasedstudy
AT siemensdrobert venousthromboembolismandperioperativechemotherapyformuscleinvasivebladdercancerapopulationbasedstudy
AT boothchristopherm venousthromboembolismandperioperativechemotherapyformuscleinvasivebladdercancerapopulationbasedstudy